Recursion Pharmaceuticals (RXRX) Long-Term Deferred Tax (2024 - 2026)

Recursion Pharmaceuticals' Long-Term Deferred Tax history runs 3 years deep, the most recent figure standing at $957000.0 for Q1 2026.

• Quarterly Long-Term Deferred Tax fell 52.22% year-over-year to $957000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $957000.0 (down 52.22% YoY) and the FY2025 annual result came in at $957000.0, down 50.52% from the prior year.
• Long-Term Deferred Tax was $957000.0 for Q1 2026 at Recursion Pharmaceuticals, roughly flat from $957000.0 in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $2.0 million in Q1 2025 and bottomed at $957000.0 in Q2 2025.
• A 3-year average of $1.3 million and a median of $957000.0 in 2025 frame the typical range for Long-Term Deferred Tax.
• Annual changes were most pronounced in 2025 — Long-Term Deferred Tax slumped 50.52% — and 2026, when it sank 52.22%.
• Recursion Pharmaceuticals' Long-Term Deferred Tax stood at $1.9 million in 2024, then slumped by 50.52% to $957000.0 in 2025, then changed by 0.0% to $957000.0 in 2026.
• Business Quant data shows RXRX's Long-Term Deferred Tax at $957000.0 in Q1 2026, $957000.0 in Q4 2025, and $957000.0 in Q3 2025.